The DIRECT study in the neoadjuvant setting, in women with early breast cancer, did not shown a benefit of a fasting mimicking diet (FMD) (3 days of low calorie, low carbohydrate and protein before each chemotherapy cycle) for achieving pathological complete response in women with stage II–III HER2-negative breast cancer [25]. This evidence concerns the gene ERBB2 and breast carcinoma.